Associate Chief of the Hematology/Oncology Division
Director of the Blood and Marrow Transplant Program, UM Marlene and Stewart Greenebaum Comprehensive Cancer Center
UMMC, Room N9E12
Education and Training
06/1982: B.S., Massachusetts Institute of Technology, Cambridge, MA
06/1986: M.D., Harvard Medical School, Boston, MA
06/1989: Postgraduate Fellowship, University of Rochester/Strong Memorial Hospital
06/1993: Postgraduate Fellowship, University of Rochester/Strong Memorial Hospital
I am a board-certified hematologist and stem cell transplant physician with more than 25 years of experience in the care of patients with hematopoietic neoplasms and benign hematologic disorders. In relation to the current grant, I have conducted translational research focused on the use of costimulated autologous T cells and vaccines to enhance immune recovery after autologous stem cell transplants for hematologic malignancies. Between 1998 and 2015, I have directed 6 major clinical trials of adoptive T-cell therapy that have enrolled more than 150 patients. Our group was among the first to show that combination immunotherapy using vaccine-primed and ex vivo costimulated autologous T cells could induce robust vaccine-specific immune responses early after autologous stem cell transplantation (ASCT) for myeloma. We also demonstrated for the first time that early adoptive transfers of costimulated T cells could induce robust T-cell recovery posttransplant and elicit graft-versus-host disease–like reactions in the autologous transplant setting. In recent work, we described a novel combination of activated T cells, tumor antigen vaccine (MAGE-A3), and a novel vaccine adjuvant (Poly-ICLC), which generated a high frequency of tumor antigen vaccine–specific T-cell responses (>70 percent) after ASCT for myeloma. In another major clinical trial, we have utilized high-affinity T-cell receptor (TCR) gene-modified T cells for adoptive cellular therapy after ASCT for myeloma. The engineered T cells expanded, persisted, trafficked to marrow, and exhibited cytotoxic function. These clinical trials have provided a new avenue for rapid reconstitution of T-cell–mediated immunity following blood/marrow transplantation and laid the groundwork for the development of effective cellular immunotherapy of myeloma.
Cancer, Vaccine, Myeloma
Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015 Aug;21(8):914–21. PubMed PMID: 26193344.
Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YY, et al. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res. 2014 Mar 1;20(5):1355–65. PubMed PMID: 24520093.
Rapoport AP, Stadtmauer EA, Aqui N, Badros AZ, Cotte J, et al. Restoration of immunity in lymphopenic cancer patients by vaccination and adoptive T-cell transfer. Nat Med. 2005 Nov;11(11):1230–7. PubMed PMID: 16227990.
Rapoport AP, Aqui N, Stadtmauer EA, Vogl DT, Fang HB, Cai L, Janofsky S, Chew A, Akpek G, Badros AZ, Yanovich S, Tan M, Veloso E, Pasetti M, Cross A, Philip S, Murphy H, Bhagat R, Zheng Z, Milliron T, Cotte J, Cannon A, Levine BL, Vonderheide RH, June CH. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination based on hTERT and surviving following ASCT for myeloma. Blood. 2011; 117(3): 788-797. Pre-published online October 28, 2010.
Ongoing Research Support
R01-CA166961 Rapoport (PI)09/01/2012–08/31/2015
Adoptive Transfer of Gene-Modified Autologous T-Cells Post ASCT for Myeloma
Senior Research Award, Rapoport (PI) 07/15/2013–07/14/2015
Multiple Myeloma Research Foundation
Immunotherapy After ASCT for MM Using MAGE-A3/Poly-ICLC-Primed T-cells
Completed Research Support
3R21CA130293-02S1 (ARRA) Rapoport (PI) 2009–2010
Immunotherapy After ASCT for MM Using hTERT Vaccination + Vaccine-Primed T Cells